New development in von Willebrand disease

Current Opinion in Hematology

Volumn 20, Issue 5, 2013, Pages 424-429

  Castaman, Giancarlo ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

desmopressin; endothelial cells; factor VIII; human mutations; inherited bleeding disorders; von Willebrand disease; von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

AUTOSOMAL DOMINANT INHERITANCE; BLEEDING TENDENCY; CARBOHYDRATE ANALYSIS; GENE MUTATION; GLYCOSYLATION; HUMAN; MISSENSE MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SHEAR STRESS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ADHESION; TRANSIENT TRANSFECTION; VON WILLEBRAND DISEASE;

BLOOD PLATELETS; HEMORRHAGE; HUMANS; RISK FACTORS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84883270104     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328363c11f     Document Type: Review

References (46)

1. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113:5049-5057.
2. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69:454-459.
3. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123:893-898.
4. Mannucci PM. von Willebrand factor: a prima ballerina on two different stages. Semin Hematol 2005; 42:1-4.
5. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6:217-246.
6. Zhou YF, Eng ET, Zhu J, et al. Sequence and structure relationships within von Willebrand factor. Blood 2012; 120:449-458.
7. Valentijn KM, Eikenboom J. Weibel-Palade bodies: a window to von Willebrand disease. J Thromb Haemost 2013; 11:581-592.
8. James PD, Goodeve AC. von Willebrand disease. Genet Med 2011; 13:365-376.
9. Haberichter SL, Fahs SA, Montgomery RR. Von Willebrand factor storage and multimerization: 2 independent intracellular processes. Blood 2000; 96: 1808-1815.
10. Rosenberg JB, Haberichter SL, Jozwiak MA, et al. The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. Blood 2002; 100:1699-1706.
11. Michaux G, Hewlett LJ, Messenger SL, et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood 2003; 102:2452-2458.
12. Hommais A, Stepanian A, Fressinaud E, et al. Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion. J Thromb Haemost 2006; 4:148-157.
13. Castaman G, Giacomelli SH, Jacobi P, et al. Homozygous type 2N R854W von Willebrand factor is poorly secreted and causes a severe von Willebrand disease phenotype. J Thromb Haemost 2010; 8:2011-2016.
14. Wang JW, Groeneveld DJ, Cosemans G, et al. Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation. Haematologica 2012; 97:859-866.
15. Castaman G, Giacomelli SH, Jacobi PM, et al. Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation. J Thromb Haemost 2012; 10:951-958.
16. Jacobi PM, Gill JC, Flood VH, et al. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood 2012; 119:4543-4553.
17. Haberichter SL, Budde U, Obser T, et al. The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF. Blood 2010; 115:4580-4587.
18. Starke RD, Paschalaki KE, Dyer CE, et al. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood 2013; 121:2773-2784.
19. Wang JW, Bouwens EA, Pintao MC, et al. Analysis of storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from von Willebrand disease patients. Blood 2013; 121:2762-2772.
20. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691-1695.
21. Lenting PJ, van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5:1353-1360.
22. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111:3540-3545.
23. Castaman G, Tosetto A, Eikenboom JC, et al. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost 2010; 8:2078-2080.
24. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108:3344-3351.
25. Van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008; 112:1704-1712.
26. Lenting PJ, Casari C, Christophe OD, et al. von Willebrand factor: the old, the new and the unknown. J Thromb Haemost 2012; 10:2428-2437.
27. Rastegarlari G, Pegon JN, Casari C, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood 2012; 119:2126-2134.
28. Castaman G, Tosetto A, Rodeghiero F. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. J Thromb Haemost 2009; 7 (Suppl. 1):71-74.
29. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002; 99:180-184.
30. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279:12102-12105.
31. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111:3531-3539.
32. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM- 1VWD). Blood 2008; 111:4979-4985.
33. Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005; 3:2228-2237.
34. Eikenboom J, Federici AB, Dirven RJ, et al. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013; 121:2336-2339.
35. Rodeghiero F, Castaman G, Tosetto A. How we treat von Willebrand disease? Blood 2009; 114:1158-1165.
36. Castaman G, Rodeghiero F. Advances in the diagnosis and management of type 1 von Willebrand disease. Expert Rev Hematol 2011; 1:95-106.
37. Bolton-Maggs PH, Patterson DA, Wensley RT, et al. Definition of the bleeding tendency in factor XI-deficient kindreds -a clinical and laboratory study. Thromb Haemost 1995; 73:194-202.
38. Sramek A, Eikenboom JC, Briet E, et al. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155:1409-1415.
39. McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104:159-165.
40. Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of von Willebrand disease type 1: an international, multicenter study. J Thromb Haemost 2005; 3:2619-2626.
41. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109:112-121.
42. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2006; 4:766-773.
43. Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10:632-638.
44. Castaman G, Tosetto A, Federici AB, et al. Bleeding tendency and efficacy of antihaemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 2011; 105:647-654.
45. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113:526-534.
46. De Wee EM, Sanders YV, Mauser-Bunschoten EP, et al. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108:683-692.